Urapidil

产品说明书

Print
Chemical Structure| 34661-75-1 同义名 : -
CAS号 : 34661-75-1
货号 : A692483
分子式 : C20H29N5O3
纯度 : 98%
分子量 : 387.48
MDL号 : MFCD00133908
存储条件:

Pure form Sealed in dry, room temperature

In solvent -20°C:3-6个月-80°C:12个月

溶解度 : -
动物实验配方:
生物活性
描述 Urapidil is a α1 adrenoreceptor antagonist and a 5-HT1A receptor agonist. Urapidil does not affect vascular tone at concentrations up to 10-5 M. Urapidil (10-5 M) markedly inhibits the alpha 1-adrenergic agonist (phenylephrine)-induced concentration-dependent contractions in aortic rings without endothelium and also to some extent in those with endothelium. Moreover, the inhibitory effect of Urapidil is more pronounced in rings without endothelium than in those with endothelium[3]. It has an alpha 1-blocking action, a weak beta 1-blocking effect, an interaction with a serotonin receptor and a central depression of sympathetic tone. Urapidil is well absorbed orally with a bioavailability of about 70% and a time to peak concentration of about 4 hours after a sustained release capsule. It is metabolized in the liver at a half-life of 4.7 hours. Urapidil does not inhibit the exercise increase in heart rate[4]. Urapidil has also been shown to improve glucose and lipid metabolism in hypertensive patients with concomitant diabetes and/or hyperlipidemia[5]. Urapidil, in contrast to nicardipine and clevidipine, preserves the hypoxia-triggered vasoconstriction in isolated pulmonary arteries[6].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00716079 - Completed - -
NCT00716079 Intracerebral Hemorrhage ... 展开 >> Stroke Hypertension 收起 << Not Applicable Completed - -
NCT02795377 - Completed - Germany ... 展开 >> Division of Cardiology, Pulmonology and Vascular Medicine Duesseldorf, Duesseldorf, NRW, Germany, 40225 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.58mL

0.52mL

0.26mL

12.90mL

2.58mL

1.29mL

25.81mL

5.16mL

2.58mL

参考文献

[1]Ramage AG. The mechanism of the sympathoinhibitory action of urapidil: role of 5-HT1A receptors. Br J Pharmacol. 1991 Apr;102(4):998-1002.

[2]Eltze M. Investigations on the mode of action of a new antihypertensive drug, urapidil, in the isolated rat vas deferens. Eur J Pharmacol. 1979 Oct 26;59(1-2):1-9.

[3]Bopp C, Auger C, Diemunsch P, Schini-Kerth V. The effect of urapidil, an alpha-1 adrenoceptor antagonist and a 5-HT1A agonist, on the vascular tone of the porcine coronary and pulmonary arteries, the rat aorta and the human pulmonary artery. Eur J Pharmacol. 2016 May 15;779:53-8

[4]Prichard BN, Tomlinson B, Renondin JC. Urapidil, a multiple-action alpha-blocking drug. Am J Cardiol. 1989 Aug 15;64(7):11D-15D

[5]Buch J. Urapidil, a dual-acting antihypertensive agent: Current usage considerations. Adv Ther. 2010 Jul;27(7):426-43

[6]Bopp C, Auger C, Mebazaa A, Joshi GP, Schini-Kerth VB, Diemunsch P. Urapidil, but not dihydropyridine calcium channel inhibitors, preserves the hypoxic pulmonary vasoconstriction: an experimental study in pig arteries. Fundam Clin Pharmacol. 2019 Oct;33(5):527-534